HONG KONG – Chinese drugmaker Luye Pharma Group Ltd. said it filed an NDA submission to the U.S. FDA for Rykindo, its novel risperidone extended-release microsphere for injection, to treat schizophrenia and bipolar disorder. It could become the first innovative drug developed by China to get marketing clearance in the U.S.